Acceleron Reports Second Quarter 2021 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. DAL
9. TMUS
10. VZ

Go back to Acceleron Reports Second Quarter 2021 Financial Results

Acceleron Pharma (XLRN) Tops Q2 EPS by 7c

August 5, 2021 4:29 PM EDT

Acceleron Pharma (NASDAQ: XLRN) reported Q2 EPS of ($0.81), $0.07 better than the analyst estimate of ($0.88). Revenue for the quarter came in at $27.94 million versus the consensus estimate of $33.44 million.

We were very pleased to highlight clinical updates from the PULSAR and SPECTRA Phase 2 trials of sotatercept reported at the annual ATS medical meeting and outline our plans for future long-term growth in rare pulmonary diseases at our Research & Development Day during... More